• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pivotal Trials Testing the Efficacy of Novel Anticoagulants for Preventing Emerging Cardioembolic Risk Entities.

作者信息

Wachter Rolf, Haeusler Karl Georg

机构信息

Department of Cardiology Universitätsklinikum Leipzig Leipzig Germany.

Department of Neurology Universitätsklinikum Würzburg (UKW) Würzburg Germany.

出版信息

J Am Heart Assoc. 2024 Jun 4;13(11):e033926. doi: 10.1161/JAHA.124.033926. Epub 2024 May 28.

DOI:10.1161/JAHA.124.033926
PMID:38804233
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11255643/
Abstract
摘要

相似文献

1
Pivotal Trials Testing the Efficacy of Novel Anticoagulants for Preventing Emerging Cardioembolic Risk Entities.检验新型抗凝剂预防新出现的心源性栓塞风险实体疗效的关键试验。
J Am Heart Assoc. 2024 Jun 4;13(11):e033926. doi: 10.1161/JAHA.124.033926. Epub 2024 May 28.
2
[Recent development of anticoagulation in stroke prevention for atrial fibrillation].[心房颤动卒中预防中抗凝治疗的最新进展]
Nihon Rinsho. 2014 Jul;72(7):1282-6.
3
Covert atrial fibrillation and atrial high-rate episodes as a potential cause of embolic strokes of undetermined source: Their detection and possible management strategy.隐匿性心房颤动和心房高频率发作作为不明来源栓塞性卒中的潜在病因：其检测及可能的管理策略
J Cardiol. 2018 Jul;72(1):1-9. doi: 10.1016/j.jjcc.2018.03.002. Epub 2018 Mar 31.
4
Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence.心房高频事件：患病率、卒中风险、对管理的影响以及证据中的临床空白。
Europace. 2019 Oct 1;21(10):1459-1467. doi: 10.1093/europace/euz172.
5
Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation.非瓣膜性心房颤动的二级卒中预防
South Med J. 2016 Nov;109(11):721-729. doi: 10.14423/SMJ.0000000000000552.
6
Atrial high-rate episodes and stroke prevention.心房高频事件与卒中预防。
Europace. 2017 Feb 1;19(2):169-179. doi: 10.1093/europace/euw279.
7
Anticoagulants for stroke prevention in nonvalvular atrial fibrillation: new agents and an updated understanding.非瓣膜性心房颤动患者预防卒中的抗凝药物：新药物及最新认识
Tex Heart Inst J. 2012;39(4):517-25.
8
Reexamination of the Embolic Stroke of Undetermined Source Concept.再探不明来源栓塞性脑卒中概念。
Stroke. 2021 Aug;52(8):2715-2722. doi: 10.1161/STROKEAHA.121.035208. Epub 2021 Jul 1.
9
Stroke: Atrial fibrillation, stroke prevention therapy and aging.中风：心房颤动、中风预防治疗与衰老
Nat Rev Cardiol. 2009 Jul;6(7):448-50. doi: 10.1038/nrcardio.2009.98.
10
Anticoagulation management in clinical practice: preventing stroke in patients with atrial fibrillation.临床实践中的抗凝管理：预防心房颤动患者的中风。
Heart Lung. 2012 Mar-Apr;41(2):146-56. doi: 10.1016/j.hrtlng.2011.07.008. Epub 2011 Nov 1.

本文引用的文献

1
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial.阿哌沙班预防心房心肌病所致隐源性卒中后复发的疗效：ARCADIA 随机临床试验。
JAMA. 2024 Feb 20;331(7):573-581. doi: 10.1001/jama.2023.27188.
2
Apixaban versus Aspirin for Embolic Stroke of Undetermined Source.阿哌沙班与阿司匹林用于不明来源栓塞性脑卒中的比较。
NEJM Evid. 2024 Jan;3(1):EVIDoa2300235. doi: 10.1056/EVIDoa2300235. Epub 2023 Dec 22.
3
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2023 ACC/AHA/ACCP/HRS 指南：心房颤动的诊断与管理——美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.
4
Atrial fibrillation first detected after stroke: is timing and detection intensity relevant for stroke risk?卒中后首次检测到心房颤动：时间和检测强度与卒中风险相关吗？
Eur Heart J. 2024 Feb 1;45(5):396-398. doi: 10.1093/eurheartj/ehad744.
5
Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h.在心房高率事件持续时间≥24 h 的患者中使用依度沙班进行抗凝治疗。
Eur Heart J. 2024 Mar 7;45(10):837-849. doi: 10.1093/eurheartj/ehad771.
6
Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.直接口服抗凝剂预防器械检测到的心房颤动患者卒中：NOAH-AFNET 6 和 ARTESiA 试验的研究水平荟萃分析。
Circulation. 2024 Mar 26;149(13):981-988. doi: 10.1161/CIRCULATIONAHA.123.067512. Epub 2023 Nov 12.
7
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.阿哌沙班预防非瓣膜性心房颤动的卒中。
N Engl J Med. 2024 Jan 11;390(2):107-117. doi: 10.1056/NEJMoa2310234. Epub 2023 Nov 12.
8
Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack.卒中和短暂性脑缺血发作后检出的心房颤动的新分类。
Lancet Neurol. 2024 Jan;23(1):110-122. doi: 10.1016/S1474-4422(23)00326-5. Epub 2023 Oct 12.
9
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.在伴有心房快速发作的患者中使用依度沙班进行抗凝治疗。
N Engl J Med. 2023 Sep 28;389(13):1167-1179. doi: 10.1056/NEJMoa2303062. Epub 2023 Aug 25.
10
Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism-the Find-AF 2 study-rationale and design.强化心律监测以降低缺血性卒中和全身性栓塞——房颤发现2研究——原理与设计
Am Heart J. 2023 Nov;265:66-76. doi: 10.1016/j.ahj.2023.06.016. Epub 2023 Jul 7.